Catalyst Pharmaceuticals (CPRX) Tops Q4 EPS by 37c, Offers Guidance

Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q4 EPS of $0.68, $0.37 better than the analyst estimate of $0.31. Revenue for the quarter came in at $152.6 million versus the consensus estimate of $141.49 million.

GUIDANCE:

Catalyst Pharmaceuticals sees FY2026 revenue of $615-645 million, versus the consensus of $615.6 million.

For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.

You May Also Be Interested In

• BTIG Starts IQM Quantum Computers (IQMX) at Buy, PT $20
• StubHub (STUB) call put ratio 2.7 calls to 1 put as share price near low end of range
• Edgewise Therapeutics Inc. (EWTX) 2K contracts of September 45 and October 50 calls active